Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of NGN-401 in Subjects With Rett Syndrome (Embolden)

NCT05898620 is registered in ClinicalTrials.gov with Neurogene Inc. as lead sponsor.

NCT NCT05898620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05898620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of NGN-401 in Subjects With Rett Syndrome (Embolden)
Lead sponsor
Neurogene Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 13, 2023
Completion date
December 31, 2029
Enrollment
33 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

rett syndrome